Mustang Bio, Inc. Change in intangibles (net)

Change in intangibles (net) of MBIO for past 10 years: annual, quarterly and twelve month trailing (TTM) including Change in intangibles (net) growth rates and interactive chart.


Highlights and Quick Summary

  • Change in intangibles (net) for the quarter ending September 29, 2021 was $-530 Thousand (a -29.33% decrease compared to previous quarter)
  • Year-over-year quarterly Change in intangibles (net) decreased by -63.95%
  • Annual Change in intangibles (net) for 2020 was $-2.49 Million (a 84.22% increase from previous year)
  • Annual Change in intangibles (net) for 2019 was $-1.35 Million (a 25.58% increase from previous year)
  • Annual Change in intangibles (net) for 2018 was $-1.08 Million (a -54.74% decrease from previous year)
  • Twelve month Change in intangibles (net) ending September 29, 2021 was $-3.52 Million (a 8.65% increase compared to previous quarter)
  • Twelve month trailing Change in intangibles (net) increased by 34.24% year-over-year
Trailing Change in intangibles (net) for the last four month:
29 Sep '21 29 Jun '21 30 Dec '20 29 Sep '20
$-3.52 Million $-3.24 Million $-2.99 Million $-2.62 Million
Visit stockrow.com/MBIO for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Change in intangibles (net) of Mustang Bio, Inc.

Most recent Change in intangibles (net)of MBIO including historical data for past 10 years.

Interactive Chart of Change in intangibles (net) of Mustang Bio, Inc.

Mustang Bio, Inc. Change in intangibles (net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-0.53 $-0.75
2020 $-0.77 $-1.47 $-0.25 $-2.49
2019 $-0.5 $-0.4 $-0.25 $-0.2 $-1.35
2018 $0.0 $-1.0 $0.0 $-0.08 $-1.08
2017 $0.0 $-1.8 $-0.2 $-0.38 $-2.38

Business Profile of Mustang Bio, Inc.

Sector: Healthcare
Industry: Biotechnology
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.